Management Team

, Dr. , Niclas Stiernholm , , President and Chief Executive Officer

Dr. Stiernholm's primary responsibilities include overseeing the company's strategic direction, executing business development plans and ensuring that our scientific programs are properly funded and advance according to schedule. Dr. Stiernholm became our President and Chief Executive Officer on our merger with the private company Trillium Therapeutics in April 2013. He joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office. He currently serves on the board of Vasomune Therapeutics. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.

Expand

, Dr. , Bob Uger , , Chief Scientific Officer

Dr. Uger is responsible for developing and implementing our scientific direction, and oversees both internal product development and external research discovery programs. He also acts as our scientific liaison with respect to global collaborations with academic and hospital research scientists. Dr. Uger was previously Vice-President, Research & Development at Trillium Therapeutics (private company). He joined Trillium from Aventis Pasteur where he was a Senior Research Scientist involved in cancer vaccine research. He received his Ph.D. in immunology from the University of Toronto.

Expand

, Dr. Eric Sievers , , Chief Medical Officer

Dr. Sievers is responsible for the design and execution of the company’s clinical and regulatory strategy. From 2006 to 2015, he served in several senior roles at Seattle Genetics, most recently as Senior Vice President, Clinical Development. At Seattle Genetics, he helped write and supervise pivotal trials that ultimately led to the US registration of ADCETRIS for Hodgkin lymphoma and anaplastic large cell lymphoma in 2011, now approved in over 45 countries worldwide. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for more than a decade. Dr. Sievers received both a B.A. in Biology and an M.D. from Brown University.

Expand

, Mr. , James Parsons , , Chief Financial Officer

Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration. He has an extensive background in the life sciences industry and over 25 years of financial management experience. His past involvement in biotechnology includes roles with Amorfix Life Sciences Ltd, DiaMedica Inc, Trillium Therapeutics Inc and YM BioSciences Inc. Mr. Parsons serves on the board of Sernova Corp where he chairs the audit committee. He has a Master of Accounting degree from the University of Waterloo and is a Chartered Professional Accountant and Chartered Accountant.

Expand

, Dr. , Penka Petrova , , Chief Development Officer

Dr. Petrova is responsible for managing the company's formal drug development efforts, including all outsourced activities to contract manufacturers and contract research organizations. In addition, she continues to serve as the Head of TTI's cell biology group and oversees all of our in vivo studies. Dr. Petrova was previously Director, Drug Development at Trillium Therapeutics (private company). She joined Trillium from Prescient Neuropharma in 2003, where she held a Research Scientist position and was involved in identifying and characterizing novel proteins involved in neuroprotection. Dr. Petrova received her Ph.D. in Microbiology from Saarland University in Saarbruecken, Germany, where she also conducted her postdoctoral studies.

Expand

, Dr. , Malik Slassi , , Senior Vice President, Discovery Research

Dr. Slassi was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. Dr. Slassi has over 25 years of experience in the successful identification of small molecule drug candidates across multiple therapeutic areas including Oncology, Neurology and Gastro-intestinal. Prior to founding Fluorinov, Dr. Slassi was Director and Vice President of Medicinal Chemistry, Manufacturing & Drug Development at NPS Pharmaceuticals and Cascade Therapeutics, respectively and earlier he held management and scientific positions at Allelix Biopharmaceuticals Inc., Boehringer Ingelheim Research Inc., and Rhône Poulenc. During his career he has been involved in numerous multinational R&D collaborations including with Hoechst AG (Sanofi-Aventis), AstraZeneca, Johnson & Johnson, Forest Laboratories, GlaxoSmithKline, and Memory Pharmaceuticals. For seven years, he served on the steering committee for the multinational collaboration on the metabotropic Glutamate Receptors (mGluRs) program between NPS and AstraZeneca. Dr. Slassi has a strong track record of drug development with over 16 drug candidates advanced into late-stage preclinical and clinical development. He is an inventor with over 130 issued and published patents and patent applications, and author of more than 65 scientific and review articles published in international peer reviewed journals. Dr. Slassi holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.

Expand

, Mr. , Scott Duncan , , Director of Intellectual Property

Mr. Duncan is recognized for the quality of his patent consulting services which he has provided for the past 30 years to a diverse range of biotechnology companies since he built and managed Canada’s largest biotech patent estate during his tenure with Allelix, one of Canada's initial biotech companies that was acquired by NPS Pharmaceuticals. His responsibilities within that role included the development of patent assets relating to transgenic crops, medicinal chemistry, protein drugs and expression systems, and in vitro diagnostics. Mr. Duncan has been a registered patent agent since 1986, when he qualified magna cum laude while working at a Toronto firm specializing in intellectual property.

Expand
More > More > More >

Recent Presentations

Thumb Date Download
Nov 18, 2017 SNO 2017 Abstract 4329 684 KB
Sep 26, 2017 Q3 2017 Corporate Presentation 2.87 MB
Jun 05, 2017 2017 ASCO Annual Meeting 415 KB
Apr 03, 2017 AACR 2017 Abstract #2646 9.96 MB
Apr 03, 2017 AACR 2017 Abstract #2653 720 KB

EMAIL ALERTS

Email Address: *
First Name:
Mailing Lists

 
Enter the code shown above.

Powered By Q4 Inc. 5.2.0.9